On the Second Day of the 93rd API China: ECHEMI Advances Global Dialogue in the Pharmaceutical Industry Through Innovative Practices

On November 13, the 93rd China International API/Intermediates/Packaging/Equipment Fair (API China) entered its second day, with on-site activity and enthusiasm continuing to rise. As a leading enterprise in the digitalization and international distribution of the pharmaceutical supply chain, ECHEMI continues to empower customer growth through its products and platform. Today, ECHEMI invited a pharmaceutical expert from Bangladesh to share regional market insights, injecting fresh global perspectives into the industry.

On the second day of the exhibition, the 70,000+ square meter venue continued to gather thousands of outstanding companies from around the world, welcoming streams of professional visitors. From APIs and excipients to pharmaceutical equipment and contract services, the entire industry chain is seamlessly integrated here. Complemented by a series of forward-looking forums held concurrently, this year’s API China—as a highly influential industry platform—continues to empower innovation and collaborative development across China’s pharmaceutical sector.

At booth N7Q05, ECHEMI showcased its core product lines in innovative APIs, intermediates, and fine chemicals, while presenting a comprehensive view of how its digital platform supports global supply chain management, cross-border resource integration, and trade transformation for pharmaceutical enterprises.

Leveraging years of industry experience, an international network, and digital tools, ECHEMI is committed to improving procurement efficiency and reducing supply chain risks for pharmaceutical companies. The company provides one-stop services covering product sourcing, quality audits, and cross-border logistics. Participation in this exhibition further highlights ECHEMI’s comprehensive service capabilities driven by both digitalization and supply chain expertise, offering strong support for pharmaceutical enterprises to expand partnerships and optimize their global footprint.

As an official media partner of API China, ECHEMI invited senior Bangladeshi pharmaceutical expert Ashikujaman Syed to deliver an in-depth analysis of the pharmaceutical market in Bangladesh.

In his presentation, Mr. Ashikujaman Syed provided a systematic examination of the structural characteristics and development trends of the Bangladeshi pharmaceutical market. He pointed out that the country has significant growth potential in APIs, intermediates, and veterinary medicines. He emphasized that as domestic pharmaceutical manufacturing capacity expands and regulatory policies improve, Bangladesh is seeing rapidly growing demand for high-quality APIs and professional veterinary products. In addition, Mr. Syed shared key market-entry strategies, including how to work with local partners to navigate regulatory compliance, leverage policy direction, and identify high-potential opportunities in localized API production and veterinary medicine segments.

Through these professional insights, ECHEMI offered exhibitors practical, actionable guidance for entering regional markets, helping Chinese enterprises expand into emerging Southeast Asian markets.

With its dual strengths in distribution + media, ECHEMI played a unique role at this year’s API China. As a professional API manufacturer and distributor, ECHEMI leverages global supply chain resources and digital tools to help clients achieve efficient, precise product sourcing and procurement execution. As an industry media platform, ECHEMI builds bridges for knowledge sharing and industry communication through content planning, expert interviews, and market insight reports—continuously enhancing industry perception and connecting resources.

At the 93rd API China, ECHEMI showcased product-driven strength while deepening cooperation with pharmaceutical peers through its digital platform and global network. The company also demonstrated its capability to support the global expansion and digital transformation of pharmaceutical enterprises.